Trial Profile

A Clinical Trial of the Drug Combination (Difluoromethylornithine and AMXT 1501) in Diffuse Intrinsic Pontine Gliomas (DIPG) in Children

Status: Planning

Phase of Trial: Phase I

Latest Information Update: 22 Feb 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

16 Feb 2021 According to an Aminex Therapeutics media release, Associate Professor Ziegler said that clinical trials of the drug combination (difluoromethylornithine (DFMO) and AMXT 1501) in DIPG are planned to begin this year in children in the global study led by the Childrens Cancer Institute and the Kids Cancer Centre at Sydney Childrens Hospital in collaboration with Aminex Therapeutics.
05 Feb 2019 New trial record
30 Jan 2019 According to an Aminex Therapeutics media release, this trial will begin, when the initial adult trial is complete.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com